Rozera Gabriella, Fabbri Gabriele, Lorenzini Patrizia, Mastrorosa Ilaria, Timelli Laura, Zaccarelli Mauro, Amendola Alessandra, Vergori Alessandra, Plazzi Maria Maddalena, Cicalini Stefania, Antinori Andrea, Capobianchi Maria Rosaria, Abbate Isabella, Ammassari Adriana
Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy.
Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy.
PLoS One. 2017 Oct 27;12(10):e0187095. doi: 10.1371/journal.pone.0187095. eCollection 2017.
Aim was to determine the dynamics of peripheral blood mononuclear cells (PBMC)- associated total HIV-1 DNA in successfully ART-treated HIV/HCV co-infected patients receiving DAA treatment and to explore possible virological hypotheses underlying the phenomenon.
Longitudinal, single-centre study measuring total HIV-1 DNA before the start of DAA, at the end of treatment (EOT), and 3 months after treatment. Univariable and multivariable analyses were used to assess factors associated with HIV-1 DNA increase ≥0.5 Log copies/million PBMC. Episomal 2-LTR forms, residual HIV-1 viremia and proviral DNA quasispecies evolution were also investigated.
119 successfully ART-treated HIV/HCV co-infected patients were included. Median baseline HIV-1 DNA was 3.84 Log copies/million PBMC (95%CI 3.49-4.05), and no significant variation with respect to baseline was found at EOT and after 3 months of DAA termination. In 17% of cases an increase ≥0.5 Log copies/million PBMC was observed at EOT compared to baseline. HIV-1 DNA increase was independently associated with lower baseline HIV-1 DNA, longer HIV suppression, raltegravir-based ART and previous exposure to interferon/ribavirin for HCV treatment. In none of the patients with HIV-1 DNA increase, 2-LTR forms were detected at baseline, while in 2 cases 2-LTR forms were found at EOT, without association with residual HIV-1 RNA viremia. No evidence of viral evolution was observed.
In successfully ART-treated HIV/HCV co-infected patients receiving DAA, PBMC-associated total HIV-1 DNA was quite stable over time, but some patients showed a considerable increase at EOT when compared to baseline. A significantly higher risk of HIV DNA increase was found, in presence of lower cellular HIV reservoir at baseline. Activation of replicative-competent virus generating new rounds of viral replication seems unlikely, while mobilization of cell-associated HIV from tissue reservoirs could be hypothesized.
目的是确定接受直接抗病毒药物(DAA)治疗的成功接受抗逆转录病毒治疗(ART)的HIV/HCV合并感染患者外周血单个核细胞(PBMC)相关的总HIV-1 DNA的动态变化,并探讨该现象背后可能的病毒学假说。
一项纵向单中心研究,在DAA治疗开始前、治疗结束时(EOT)和治疗后3个月测量总HIV-1 DNA。采用单变量和多变量分析评估与HIV-1 DNA增加≥0.5 Log拷贝/百万PBMC相关的因素。还研究了游离的2-LTR形式、残余HIV-1病毒血症和前病毒DNA准种进化。
纳入了119例成功接受ART治疗的HIV/HCV合并感染患者。基线时HIV-1 DNA中位数为3.84 Log拷贝/百万PBMC(95%CI 3.49-4.05),在EOT时以及DAA治疗终止3个月后,与基线相比未发现显著变化。17%的病例在EOT时与基线相比观察到HIV-1 DNA增加≥0.5 Log拷贝/百万PBMC。HIV-1 DNA增加与较低的基线HIV-1 DNA、较长时间的HIV抑制、基于raltegravir的ART以及先前接受干扰素/利巴韦林治疗HCV独立相关。在HIV-1 DNA增加的患者中,无一例在基线时检测到2-LTR形式,而在2例患者中在EOT时发现了2-LTR形式,与残余HIV-1 RNA病毒血症无关。未观察到病毒进化的证据。
在接受DAA治疗的成功接受ART治疗的HIV/HCV合并感染患者中,PBMC相关的总HIV-1 DNA随时间相当稳定,但一些患者在EOT时与基线相比显示出显著增加。在基线时细胞内HIV储存库较低的情况下,发现HIV DNA增加的风险显著更高。激活具有复制能力的病毒产生新一轮病毒复制似乎不太可能,而从组织储存库中动员细胞相关HIV可以作为一种假说。